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FIBROBLASTS (Fb) from patients with sarcoidosis (SA) and
hypersensitivity pneumonitis (HP) exhibited a lower
proliferative capacity compared with Fb obtained from
control (CO) and diffuse interstitial fibrosis patients
(DIF). Proliferation of Fb from SA or lip patients was
suppressed by autologous LPS-stimulated alveolar
macrophages (AM) supernatants but not by those from
CO patients. Similarly, alveolar macrophages (AM) de-
rived supernatant, obtained from CO, did not suppress
the proliferation of SA and HP Fb. AM from SA and HP
patients secreted higher amounts of IL-lcx and com-
pared with controls and compared with Fb from SA and
HP patients. Steady levels of IL-ltz and mRNA were ex-
pressed in unstimulated and stimulated cultures. Fb from
SA and tip patients could be stimulated by LPS to secrete
significantly higher levels ofPGE than those detected in
supernatants from LPS stimulated Fb of DIF patients.
Only the proliferation ofFb from SA and HP patients was
sensitive to amounts of IL-1 equivalent to those detected
in the lung of these diseases. As SA and HP are two
diseases where irreversible deterioration occurs in only
20% ofthe patients, we hypothesize that mediators in the
lung may modulate Fb proliferation. IL-1 of AM origin
and PGE of Fb origin secreted at high levels, may be
candidates for this suppression because it was abrogated
by anti IL-I and indomethacin.
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Introduction
One of the most prominent histologic features of
granulomatous and interstitial diseases in the lung is
the close proximity of mononuclear cells with
fibroblasts or the matrix secreted by them. Several
studies characterized mononuclear cell-derived fac-
tors that stimulate1," or inhibit3,4 fibroblast growth and
secretory functions in vitro. Other researchers have
shown that cytokines are released spontaneously by
macrophages isolated from lungs of animals exposed
to a variety of stimulants, including cytotoxic drugs
and mineral dusts,5,6 as well as from patients with
idiopathic pulmonary fibrosis (IPF) and sarcoidosis
(SA). Furthermore, alveolar lining fluid collected by
pulmonary lavage from patients with pulmonary
fibrosis has been shown to contain fibrogenic
cytokines, such as TGF and TNFoq1 pointing to the
role of cytokines in vivo. These data suggest that
cytokines are present in situ and may .mediate. the
pathological manifestations of interstitial lung dis-
eases. Lately, efforts have been directed towards the
identification of macrophage-derived factors which
affect fibroblast growth-function, while fewer studies
were oriented towards the investigation of the im-
munoregulatory and pro-inflammatory role of fibro-
blasts. Recently, it was shown that murine fibroblasts,
stimulated by cytokines and LPS, are able to generate
IL-Iz activityha2 and that rIL-1 and TNF stimulate
normal adult human lung fibroblast to accumulate
not to secrete IL-1[3.3 Moreover, other studies dem-
onstrated that fibroblast strains secrete inflammatory
mediators, such as prostaglandin E,. (PGE2), interleu-
kin 6 (IL-6), interleukin 8 (IL-8), monocyte chemo-
attractant peptide (MCP-1) and colony-stimulating
factor.4-9 As we have previously shown that alveolar
fibroblasts can be obtained from long-term cultures
of bronchoalveolar cells recovered from patients with
SA, we decided to further characterize the interactions
between alveolar macrophages and alveolar fibro-
blasts in interstitial lung diseases in an autologous
system. Thus, in the present study we assessed the
differential secretion of IL-1 and PGE2 by these cells,
in comparison with alveolar macrophages and the
possible role of these mediators as suppressive
agents of fibroplasia and fibrosis in these diseases.
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Patients and Methods
Study population. Eighteen patients, belonging to
three groups were included in this study.
Pulmonary sarcoidosis (SA). Diagnosis was made in
six untreated patients (three males and three females,
mean age 37+ 7 years), by clinical and
roentgenological presentation, a positive Kveim test,
or a positive biopsy of non-caseating granuloma. All
patients were in Stage II sarcoidosis. None of them
was a smoker.
Diffuse interstitialfibrosis (DIF). Three patients (two
males and one female, mean age 61 + 10 years).
Diagnosis of DIF was made by roentgenological
evidence of reticular infiltration and different degrees
of interstitial fibrosis, demonstrated by
transbronchial biopsy. None of them was a smoker.
Hypersensitivity pneumonitis (HP). Three patients
belonged to this group (two males, one female, mean
age 48 + 6 years). Roentgenological evidence (X-rays
and CT scan) showed reticular nodular pattern with
predominant upper zone involvement. Broncho-
alveolar lavage (BAL) analysis demonstrated features
of a cell-mediated immune response with lympho-
cytosis. Lung histology was compatible with HP but
no attempt was made to characterize the sensitizing
antigens. None of them was a smoker.
Control. Six patients (three males and three females,
mean age 44 + 18 years) were admitted for investiga-
tion due to persistent cough. All of them presented
chest roentgenograms within normal limits. None of
them was a smoker.
None of the patients received any medicaments
prior to the study. Written consent was obtained
from each subject before bronchoscopy. Characteri-
zation of cell population present in BAL and pul-
monary function test parameters of all patients
examined are summarized in Table 1.
Methods:
Bronchoalveolar lavage (BAL). BAL was performed
using a flexible fibre optic bronchoscope (BF-B2;
Olympus Optical Co., Ltd, Tokyo, Japan) as previ-
ously described. 21 The cells were recovered by gentle
aspiration. The percentage of lavage fluid (+SD)
recovered from each group of patients was as fol-
lows: 67 + 10% from CO and 58 + 8% from ILD cases.
The average total cells recovered was 5 + 1 x 106 cells
from CO and 17 + 7 x 106 cells from ILD patients.
Preparation ofAM andAM supernatants. AM were
prepared as previously described. 21 Differential
counts were performed on a Giemsa stained
cytocentrifuge preparation (Cytospin; Shandon,
Southern Products Ltd, Runcorn, Cheshire, UK), by
counting a minimum of 500 cells. Cells were adjusted
to a final concentration of 106 cells/ml in RPMI 1640
medium, supplemented with 10% heat" inactivated
FCS, 1% t-glutamine, and 1% streptomycin, penicillin,
mycostatin complete medium (Biological Industries,
Beit Haemek, Israel). TheAM were purified by adher-
ence in a 5% CO2 humidified atmosphere for 1 h at
37C. Identification of macrophages was done by
morphology and nonspecific esterase staining and
counted with an objective micrometer (Olympus
Optical Co., Ltd, Tokyo, Japan). The adherent cell
population contained more than 90% AM.
AM were cultured in 3-cm diameter plastic Petri
dishes (Sterilin, Hounslow, Middlesex, UK) for either
24h or 72 h. The 24 h period was found to be
optimal for testing the production if IL-1 in the
presence of lipopolysaccharide (LPS-Escherichia coli
055:B5; Difco Laboratories, Detroit, USA; 10 btg/ml)
stimulated cultures. The 72 h period was chosen as
the optimal time for release of PGE2 in unstimulated
cultures. Supernatants were recovered, filtered
(Acrodisc 0.2 bt; Gelman Sciences) and stored at
-70C until determination for IL-1, and not longer
than 2 weeks for PGE2.
Table 1. BAL cells characteristics and pulmonary function tests (PFT) in all patients
Patients Mac Ly Bas Eos Neut DLCO FVC FEV FEVI/FVC TLC
SA (6)
Mean + SD 51 + 15 48 + 15"
HP (3)
Mean + SD 40 + 8 58 + 12"
DIF (3)
Mean + SD 70 + 8 13 + 13
CO (6)
Mean + SD 86 + 5 13 + 5
0.6+0.4 0.5+0.2 0.8+/-0.6 99+/-14"* 99+/-9 87+/-10 102+/-6 97+/-11
1.9+/-1 0.9+/-1.3 0.8+/-0.4 114+/-22"* 103+/-14 104+/-10 106+/-3 103+/-15
8.4+/-8"** 12+/-8"** 69+/-9 76+/-8 77+9 106+/-6 86+/-7
103 +/- 12 99 +/- 3 101 +/- 12 109 +/- 5 102 +/- 5
*p < 0.0001 compared with CO group.
**p < 0.001 compared with DIF group.
***p < 0.001 compared with CO group.
Mac macrophages; Ly lymphocytes; Bas basophils; Eos eosinophils; Neut neutrophils; DLCO diffusion lung carbon oxide; FVC
forced vital capacity; FEV forced vital capacity second one; TLC total lung capacity.
PFT were performed in all patients prior to the BAL.
Differential counts were performed by counting 500 cells of a Giemsa stain cytoprep as described in Patients and Methods.
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Preparation ofalveolarfibroblasts. The fibroblast line
was derived from the bronchoalveolar cells as pre-
viously described.2 First clones of proliferating
fibroblasts appeared after 2-3 weeks of incubation
in 3-cm diameter plastic Petri dishes (Sterilin, Houns-
low, Middlesex, UK). After reaching confluence, usu-
ally 5-6 weeks later, the explant tissue was removed
with trypsin-EDTA Type B (Biological Industries, Beit
Haemek, Israel) for 10 min and cells were split 1:2 at
confluency in 25 cm tissue plastic culture flasks
(Sterilin, Hounslow, Middlesex, UK). In all experi-
ments the cells used were from passages 4-7.
Preparation ofpulmonaryfibroblasts. Stable lines of
human pulmonary fibroblasts were used a control
cells. Lung specimens from pneumonectomy speci-
mens from patients with thoracic malignancies or
benign lesions were minced into pieces of 2-4 mm
and incubated in i x 5 cm Petri dishes (Sterilin,
Hounslow, Middlesex, UK) containing 3 ml of com-
plete DMEM. Every 72 h the non-adherent cells were
removed by washing with PBS and fresh media was
added. After 2 weeks, cultures reached confluence
and the cells were split and used as described above.
Preparation ofFb supernatants and Fb proliferation
test. Fb derived supernatants were obtained from
24 h LPS-stimulated Fb cultures cultured for 24 h with
or without LPS. Aliquots of the supematants were
frozen at-70C until used. Proliferation test was
performed as previously described.2 Briefly, 100 t.tl
of Fbs suspended at 105 Fb/ml were allowed to attach
for 1-2 h. Aliquots (50 l.tl) of supernatants of LPS-
stimulated AM were added. Proliferation was
assessed after 72 h, and pulsed with 1 laCi H-Tdr
(48 l.tCi/nmol specific activity, Rotem Industries
Ltd, Beer-Sheva, Israel) for the last 16 h of culture.
The proliferation of Fb in the presence of AM
supernatants was compared with that of Fbs DMEM
with a final concentration of 100 l.tg/ml LPS.
Assay ofprostaglandin and IL-lproduction. Aliquots
of AM and Fb supernatants (24 h production) were
assayed for PGE,. by a radioimmunoassay (Advanced
Magnetic Inc., MA, USA) and IL-10t and IL-113 produc-
tion by a RIA Kit (Amerlex-MTM Magnetic separation,
Amersham International PLC, Amersham, UK).
Isolation ofmRNA transcripts. RNA was extracted by
100 t.tl of 4.0M guanidium thiocyanate (GuSCN Sigma
Chemical Co., St Louis, USA) from adherent 106 cells/
ml stimulated (10 t-tg LPS + 10 ng/ml IL-10t and ]3 for
24 h and non-stimulated AFb. The mixture was over-
laid on to 100 l.tl of 5.7 M CsCl and RNA was isolated
after overnight ultracentrifugation at 35000 r.p.m.
(Kontron Institute, Zurich, Switzerland) at 15C. The
pellet recovered by centrifugation was resuspended
in 100 l.tl DEPC water, 300 l.tl pure ethanol and 30 t.tl
3.0 M sodium acetate. The RNA pellet (30’ at
15 000 r.p.m.) was washed (100 t.tl 80% ethanol) and
amplified using the reverse transcription-mix [RT
mix: 3 btl 200 U/l.tl MMLV, moloney murine leukaemia
virus-RT (BRL, Bethesda Research Laboratory,
Gaithesburg, MD, USA), 1 t.tl 40 U/t.tl RNAasin, 6 I.tl
5XMMLV buffer, 3 l.tl random primers (Promega CA,
Madison, USA), 3 }.tl of 1 mg/ml BSA (Sigma Chemi-
cals Co., St Louis, USA) 1.5 t-tl of 10 mM dNTP mix-
Pharmacia, Fine Chemicals AB, Uppsala; Sweden).
Each sample contained 17.5 btl and the reaction was
performed for 1 h at 42C.
PCR assay, cDNA fragments were amplified
(GeneAmp-Clontech Laboratories Inc., Palo Alto, CA,
USA) in a polymerase chain reaction (PCR) mix
containing 8 t.tl dNTPs mix 1.25 mM (Pharmacia Fine
Chemicals AB, Uppsala, Sweden) and 0.25 t.tl Taq
polymerase, 5 U/l.tl (Promega CA, Madison, USA)
using thermal cycler cells (PT-100 MJ Research Inc.,
OSP, Cambridge MA, USA). [3 actin mRNA was evalu-
ated concurrent with IL-10t and ]3 mRNA as an inter-
nal control. Products of the combined reverse tran-
scription-polymerase reaction (8 btl PCR product and
2 l-tl of gel loading buffer) were fractionated by
electrophoresis in agarose stained with ethidium
bromide and validated by matching predicted size
174/HaelII digest (Pharmacia Fine Chemicals AB,
Uppsala, Sweden).
Statistics. Student’s t-test was used for statistical
evaluations using the Epistat Software, (C) 1984, T.L.
Gustafson. The results are expressed as mean + SD
and values less than 0.05 were considered to be
significant.
Results
Effect of AM supernatants on the proliferation of
fibroblasts: The basic proliferation rate of Fb from SA
and HP patients was shown to be significantly lower
than that of Fb in the CO group (Table 2).
AM-derived supernatants were tested for effects on
the proliferation of Fb in an autologous culture set-up
and in presence of AM supematant of CO patients
(Fig. 1) and on normal Fb lines (Fig. 2). The AM
supernatants of SA and HP suppressed the prolifera-
Table 2. Proliferation rates of Fbs
Patient SA-Fb HP-Fb CO-Fb
7753 + 1007 32677 + 5257 62466 + 5528
2 9399 + 297 10509 +/- 1256 28437 +/- 2687
3 1801. +/- 437 9182 +/- 1609 25347 +/- 5630
4 7613 +/- 1007 30271 +/- 982
5 6047 +/- 268 46776 +/- 2286
6 2633 +/- 853
Mean +/- SD 5874 +/- 2771" 17459 +/- 10776** 38659 +/- 14033
Fibroblasts were cultured in complete DMEM as described in
Patients and Methods. Thymydine uptake was measured after
incubation of 72 h.
*p<0.001 compared with CO.
**p<0.001 compared with CO.
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FIG 1. Effects of AM-derived supernatants on the proliferation of autologous Fb. Fb were incubated for 72 h in DMEM (2% FCS, antibiotics, antimycotic)
in the presence or absence of autologous supernatants. (a) Six cases: R Fb incubated in DMEM; J Fb incubated in DMEM + autologous AM supernatant
of SA patients; [] Fb incubated in DMEM + AM supernatant of CO patients. (b) Left side, three HP cases; right, two DIF cases: R Fb incubated in DMEM;
1 Fb incubated in DMEM + autologous AM supernatant of HP and DIF patients; [] Fb incubated in DMEM + AM supernatant of CO patients.
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FIG. 2. Effects of AM-derived supernatants on the proliferation of control Fb. Fb were incubated for 72 h in DMEM (2% FCS, antibiotics, antimycotic) in the
presence or absence of supernatants. (a) Six cases: Fb incubated in DMEM; 1 Fb incubated in DMEM + AM supernatants of SA patients; [] Fb
incubated in DMEM + AM supernatants of CO patients. (b) From left to right: HP three cases; CO three cases; DIF and CO one case: Fb incubated
in DMEM; Fb incubated in DMEM + AM supernatants of HP and DIF; [] Fb incubated in DMEM + AM supernatants of patients.
tion of autologous Fb by 38 + 7% (Fig. la, patients
1-6, left panel) and 31 + 10% (Fig. lb, patients 1-3,
left panel), respectively. In contrast, CO AM-derived
supernatants suppressed proliferation by only 13 +
5% in four cases (Fig. la, patients 1, 3, 5 and 6, right
panel) and enhanced by 30 + 1% in two cases (Fig.
la, patients 2 and 4, right panel) when tested on Fb
of SA. When CO AM supernatants were tested on
HP-Fb, 3% suppression in two cases (Fig. lb, patients
1 and 2, right panel) and 20% enhancement in the
third case (p < 0.001 between patients groups and
controls). The SA-AM derived supernatants exerted a
differential effect when tested on normal Fb: sup-
pression of 34 + 22% in three cases (Fig. 2a, patients
1, 3 and 6, left panel) and enhancement in three
others 29 + 18% (Fig. 2a, patients 2, 4 and 5, left
panel). A similar.pattern was seen in the HP group.
Supernatants derived from DIF patients enhanced the
proliferation of Fb in all cases tested.
Thus, in the autologous culture set-up, AM-derived
supernatants from SA and HP patients exerted signifi-
cant suppression on the proliferative capacity of
alveolar Fb, which was much less pronounced when
448 Mediators of Inflammation Vol 3. 1994
tested on normal Fb. In addition, AM-derived
supernatants from control or DIF patients, did not
exert a suppressive effect on Fb proliferation.
Analysis oflL-l, IL-I and PGE2 levels in AM and
Fb supernatants: LPS-induced supernatants from AM
and Fb were tested for their ability to secrete IL-10,
[ and PGE2. As shown in Tables 3 and 4, the levels
of IL-10t and [ of stimulated SA and HP AM,
Table 3. IL-I levels in AM and Fb supernatants
Diagnosis AM Fb
-LPS +LPS -LPS +LPS
SA (6)
HP (3)
DIF (3)
CO (6)
0.17 + 0.03* 0.78 + 0.71" 0.16 + 0.05 0.17 +/- 0.05
0.13 +/- 0.0 4* 0.5 +/- 0.2** 0.14 +/- 0.05 0.2 + 0.04
0.08 +/- 0.02 0.16 +/- 0.02 0.14 +/- 0.15 0.16 +/- 0.01
0.05 +/- 0.007 0.18 +/- 0.04 0.18 +/- 0.04 0.18 +/- 0.02
"IL-I was measured in Fb supernatants by RIA as described in
Patients and Methods. Results are expressed as concentration of
IL-1 (ng/ml).
*p < 0.05 compared with CO.
**p < 0.001 compared with CO.Fibroblast proliferation in ILD
Table 4. IL-1I" levels in AM and Fb supernatants
Diagnosis AM Fb
-LPS +LPS -LPS +LPS
SA (6) 0.09 + 0.04**
HP (3) 0.08 + 0.03**
DIF (3) 0.08 + 0.02
CO (6) 0.07 + 0.02
2.1 + 2.0* 0.14 + 0.04 0.15 + 0.04
1+0.6"* 0.13+0.04 0.17+0.04
0.16 +/- 0.02 0.18 +/- 0.06 0.17 +/- 0.02
0.17 +/- 0.08 0.12 +/- 0.04 0.12 +/- 0.01
IL-1I was measured in Fb supernatants by RIA as described in
Patients and Methods. Results are expressed as concentration of
IL-1 (ng/ml).
*p< 0.05 compared with CO and DIF.
**p < 0.001 compared with CO and DIF.
were significantly higher than those of CO cultures
(2.1 + 2.0 and 1 + 0.6 ng/ml, compared with 0.17 +
0.08 ng/ml for IL-113, and 0.8 + 0.7 and 0.5 + 0.2
ng/ml compared with 0.2 + 0.04 ng/ml for IL-lz,
p < 0.05 compared with CO).
LPS did not affect the secretion if IL-10t and IL-I
and only baseline levels of those cytokines were
produced by Fb irrelevant of their source, in contrast,
when PGE secretion was assessed (Table 5) it was
demonstrated that LPS-stimulated Fb of SA and HP
patients generated significantly higher levels of PGE
(0.36 + 0.24 and 0.59 + 0.27 ng/ml in stimulated
supernatants of SA and HP patients compared with
0.16 + 0.12 and 0.23 + O.19 ng/ml in unstimulated
cultures). The high levels of PGE,. secreted by stimu-
lated Fb in SA and HP were significantly higher than
those found in Fb recovered from DIF patients (0.36
+ 0.24 and 0.59 + 0.27 ng/ml in SA and HP, compared
with 0.06 + 0.03 ng/ml in DIF, p < 0.05).
Detection ofIL-lc andIL-I mRNA transcripts in Fb:
In order to assess whether the IL-l(z and IL-I genes
are expressed in Fb of these diseases, we assessed
the mRNA transcripts by PCR. IL-10t and IL-I tran-
scripts were constitutively found in stimulated, as
well as non-stimulated, Fbs (Fig. 3a, b, c and d).
Effects of exogenous IL-I on Fb proliferation:
Exogenous IL-113 (concentrations in the range of
0.3-1000 ng/ml), were added to Fb cultures and
proliferation was assessed by the tritiated thymidine
incorporation. IL-1]3, at concentrations of 0.35-62.5
ng/ml (Fig. 4a) and 0.35-125 ng/ml (Fig. 4b) signifi-
cantly suppressed the basic proliferation rate of Fb by
46 + 1.4% and 39 + 0.9% (p < 0.001) compared with
proliferation of Fb in complete medium (Fig. 4a and
b). These concentrations include the range of IL-113
by AM of SA and HP patients (4-0.8 ng/ml). As a
general trend in Fbs of the CO group, no suppressive
activity was observed at minute concentrations of IL-
l[3 (Fig. 4c). The modulatory effects of IL-13 were
abrogated by anti-IL-1 antibodies or indomethacin
(Table 6). A clear reversion of the suppression was
achieved in the SA and HP group, but not in the CO
and DIF groups.
Discussion
AM are present within the alveoli and bronchioli
while the fibrosis occurs in the interstitium. How-
ever, it is feasible to assume that AM affect the
process of fibrosis because of their close proximity.
The outcome of a number of interstitial lung diseases
(ILD) results in severe pulmonary fibrosis. In con-
trast, patients with SA or HP, manifesting inflamma-
tory or granulomatous diseases, usually heal without
excessive scarring. In the present study, we assessed
the fibroblast-macrophage interactions in ILD, in an
attempt to understand the differential outcome of the
diseases. We assessed the proliferative capacity of Fb
and the secretion of cytokines/inflammatory prod-
ucts by AM and Fb, the latter being the target cells
in these diseases.
We showed (Table 2) that Fb recovered from SA
and HP, display significantly lower rates of back-
ground proliferation, compared with Fb recovered
from normal tissue specimens even after serial
passages for up to 2 months. The existence of
Fb populations from fibrotic lungs which retain
enhanced proliferative potential in culture, have
already been reported’2,23 together with reports on
decreased4 or increased25 cytokine production by
fibroblasts in chronic GVHD (graft versus host dis-
Table 5. PGE2" levels in AM and Fb supernatants
Diagnosis AM Fb
-LPS +LPS -LPS +LPS
SA (6) 0.06 +/- 0.02 0.31 +/- 0.3 0.16 +/- 0.12" 0.36 +/- 0.24***
HP (3) 0.09 +/- 0.02 0.27 +/- 0.14 0.23 +/- 0.19 0.59 +/- 0.27
DIF (3) 0.5 +/- 0.3 1.2 +/- 0.5 0.6 +/- 0.03 0.06 +/- 0.03**
CO (6) 0.04 +/- 0.01 0.41 +/- 0.31 0.49 +/- 0.20 0.46 +/- 0.20
"PGE2 was measured in Fb supernatants by RIA as described in Patients and
Methods. PGE levels are expressed in ng/ml.
*p < 0.05 compared with CO.
**p < 0.01 compared with CO.
***p < 0.05 compared with DIF.
p < 0.02 compared with CO, SA and HP.
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FIG. 3. Detection of IL-lo and IL-11 mRNA transcripts in Fb. mRNA was isolated as described
in Patients and Methods and reverse transcripted in a RT reaction, cDNA fragments were
amplified in a PCR reaction. (a,b) IL-I and I transcripts of Fb in SA; (c,d) IL-I and l}
transcripts of Fb in CO. Each experiment is compared with positive transcription of actin.
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FIG. 4. Effect of exogenous IL-I on the proliferation of Fb. (a) SA Fb (basic
proliferation of Fb 6600 +/- 545 cpm). (b) HP Fb (basic proliferation of
Fb 5429 +/- 345 cpm). (c) CO Fb (basic proliferation of Fb 54173 +/- 1327
cpm).Fibroblast proliferation in ILD
Table 6. Effect of indomethacin and anti-lL-113 antibodies on IL-11 induced suppression on Fb proliferation
SA HP DIF CO
Medium 4478 +/- 235 5430 +/- 343 15726 +/- 150 54173 +/- 1327
IL-11 (1.5 ng/ml) 3561 +/- 257 3404 +/- 8 12500 +/- 500 47808 +/- 1866
IL-11 (1.5 ng/ml) 7516 + 354 5062 +/- 352 8306 +/- 914 48977 +/- 9649
+ Ind (1 #g/ml)
IL-11 (1.5 ng/ml) 5508 +/- 142 10782 +/- 1052 2648 +/- 108 46689 +/- 780
+ anti-lL-1 (20 #g/ml)
"cpm of a[H] thymidine incorporation of fibroblasts. Indomethacin and anti-lL-1 were added and cells were
incubated for 72 h. The experiment was repeated three times with similar results.
ease) and rheumatoid arthritis, respectively. The
possibility that alveolar Fb differed from control Fb
in the method of recovery seems unlikely, as it was
shown by Davis et al. 26 that alveolar lavage
fibroblasts displayed similar distributions of
interdivision time as in foetal and adult lung tissue
fibroblasts.
We showed also that AM-derived supernatants
suppressed the proliferation of autologous Fb, recov-
ered from patients with SA and HP, but not of Fb
from DIF patients or CO (Fig. la and b). However,
as described also by others,
iv AM supernatants from
SA patients, when tested on normal lung fibroblasts,
either inhibit or enhance their proliferation, and no
clear pattern of response could be concluded. These
results may indicate that our autologous culture set-
up may approximate the in vivo situation.
As SA and HP are two diseases where irreversible
deterioration in pulmonary function occurs in only
20% of patients, we hypothesize that inflammatory
mediators secreted by AM or Fb may mediate the
suppression in the proliferative capacity of
autologous Fb in SA and HP. We found here and in
previous studies’1,28 that IL-1 is actively secreted from
AM in SA and HP patients. Thus, the secretion of IL-
l together with secretion of TNFo,29-31 which may
possibly mediate the suppression of Fb proliferation
in these diseases. This observation was also con-
firmed by Elias et al.,4,2
In order to investigate the role of IL-1 in the Fb
suppression we examined first whether exogenous
stimuli can potentiate Fb to generate soluble IL-I
and [. We could detect IL-10t and IL-I[ gene tran-
scription in CO or LPS/IL-1 stimulated Fb from CO
and SA patients. Subsequently, we found that stimu-
lated and non-stimulated Fb secrete low detectable
levels of both species of IL-1 (0.12-0.17 ng/ml). The
same stimulus induced AM to produce high levels of
IL-I and [. These results are in agreement with
previous findings,4 demonstrating that stimulated
Fb contain more (1-10%) IL-1 mRNA than LPS-stimu-
lated monocytes, but they produce less detectable IL-
1[ (<0.04%). The mechanism of IL-1 secretion is still
obscure, as it lacks a signal peptide..A rote for
plasmin or plasmin-like proteases for the release of
IL-1 has been reported in macrophages.35 It may be
that this enzymatic activity is lacking in Fb. This
dichotomy between IL-1 gene transcription and
expression of biological activity has already been
demonstrated in stimulated macrophages and Fb6,7
and may suggest that IL-1 activity may be regulated
at multiple levels, such as transcription, stability of
mRNA, translation and post-translational events. In
our case, we postulate that one of these regulatory
post-transcriptional events may be mediated by
prostaglandins, as this mechanism was already
demonstrated for normal AM to suppress cytokine
production.8 In fact, we showed that only fibro-
blasts recovered from SA and HP patients may be
induced to release significant amounts of PGE upon
stimulation with LPs.
Two points have to be considered concerning the
possible involvement of IL-1 in suppressing the pro-
liferative capacity of lung Fb: (i) Fb from SA and HP
patients in vivo are exposed to high levels of IL-1 of
AM origin; (ii) the exogenous effect of this cytokine
may be differential on quiescent versus rapidly pro-
liferating fibroblasts. In fact, we tested the effects of
exogenous IL-I[ on the proliferation of normal Fb,
as well as Fb cells obtained from SA and HP patients.
Our results indicate that IL-I[, at the levels equiva-
lent to those present in the microenvironment in the
lungs of SA and HP patients (0-4 ng/ml), exerts a
suppressive effect on slowly subconfluent proliferat-
ing alveolar Fb from these diseases, whereas at levels
detected in normal lungs (0-0.2 ng/ml), enhance the
replication of actively proliferating Fb recovered
from control lungs (Fig. 3a-c). Similar dichotomic
effects have already been demonstrated for the regu-
lation of fibroblast proliferation by recombinant
interferons , 0t and [.8 Indeed, using Fb, as well as
other cell types, contrasting effects of IL-1 on cell
proliferation were reported.9-43 This may result from
differential sensitivity of various cells to the direct
mitogenic effects of IL-1 or to a distinct cytokine
cascade induced by IL-1. In our case, it may be
possible that IL-1 induces in SA and HP, Fb suppres-
sive cytokines (such as TGF-[, IL-6 and possibly IL-
l0) or other mediators (such as PGE2).
In conclusion, we postulate that the benign course
of the disease of most patients with SA and HP
involves a downregulation in the proliferative capa-
city and possibly alters the secretory function
of Fb.
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